



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	July 6, 2012 November 18, 2015

MYRBETRIO® (mirabegron)

LENGTH OF AUTHORIZATION:

Initiation of therapy: Up to 90 days
Continuation of therapy: Up to 6 months

REVIEW CRITERIA:

- Patient must be \geq 18 years old.
- Diagnosis of overactive bladder.
- The patient must have a history of trial and failure within the past 365 days of at least two other preferred indicated anticholinergic agents.

DOSING & ADMINISTRATION:

- Recommended starting dose is 25 mg once daily, with or without food
- 25 mg is effective within 8 weeks. Based on individual efficacy and tolerability, may increase dose to 50 mg once daily
- **Dosage form:** Extended-release tablets: 25 mg and 50 mg